Soleno Therapeutics Files 8-K on Financials
Ticker: SLNO · Form: 8-K · Filed: Mar 7, 2024 · CIK: 1484565
| Field | Detail |
|---|---|
| Company | Soleno Therapeutics Inc (SLNO) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $4,140, $4,410 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations, sec-filing
Related Tickers: SLNO
TL;DR
SOLENO THERAPEUTICS (SLNO) filed an 8-K on March 6, 2024, updating on financials and operations.
AI Summary
On March 6, 2024, Soleno Therapeutics, Inc. filed an 8-K report detailing its financial results and operations. The company, formerly known as Capnia, Inc., is incorporated in Delaware and headquartered in Redwood City, California. The filing includes information on its results of operations, financial condition, and regulatory disclosures.
Why It Matters
This 8-K filing provides investors with crucial updates on Soleno Therapeutics' financial health and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial and operational information, not indicating any immediate material adverse events.
Key Players & Entities
- SOLENO THERAPEUTICS, INC. (company) — Registrant
- Capnia, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Redwood City, CA (location) — Principal executive offices location
- March 6, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Soleno Therapeutics, Inc.?
The primary purpose is to report on the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements/exhibits, as of March 6, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on March 6, 2024.
What was Soleno Therapeutics, Inc. formerly known as?
Soleno Therapeutics, Inc. was formerly known as Capnia, Inc.
In which state is Soleno Therapeutics, Inc. incorporated?
Soleno Therapeutics, Inc. is incorporated in Delaware.
What is the address of Soleno Therapeutics, Inc.'s principal executive offices?
The address of Soleno Therapeutics, Inc.'s principal executive offices is 203 Redwood Shores Parkway, Suite 500, Redwood City, CA 94065.
Filing Stats: 654 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-03-07 06:06:32
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
- $4,140 — istrative expense line should have read $4,140 instead of $4,410 for the three months
- $4,410 — line should have read $4,140 instead of $4,410 for the three months ended December 31,
Filing Documents
- d764812d8k.htm (8-K) — 26KB
- d764812dex991.htm (EX-99.1) — 69KB
- g764812g0307082415750.jpg (GRAPHIC) — 3KB
- 0001193125-24-061288.txt ( ) — 228KB
- slno-20240306.xsd (EX-101.SCH) — 3KB
- slno-20240306_lab.xml (EX-101.LAB) — 18KB
- slno-20240306_pre.xml (EX-101.PRE) — 11KB
- d764812d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Soleno Therapeutics, Inc. dated March 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: March 7, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer